Perspectives on Ensifentrine and Its Therapeutic Potential in the Treatment of COPD: Evidence to Date
Muhammad Asad Faruqi, Malik Muhammad Uzair Khan, David M. Mannino
Abstract
Abstract: Ensifentrine is a novel inhalational phosphodiesterase (PDE)3 and PDE4 inhibitor which improves bronchodilation and decreases inflammatory markers by acting locally on the bronchial tissue, with minimal systemic effects. Both preclinical and clinical trials have demonstrated benefits of this therapy, including improvement in lung function and reduction in exacerbations. This therapy is currently under review by the US Food and Drug Administration with a decision expected in 2024. Keywords: chronic obstructive pulmonary disease, therapy, phosphodiesterase inhibitor
Topics & Concepts
MedicineBronchodilationCOPDRoflumilastIntensive care medicinePhosphodiesterasePulmonary diseaseClinical trialLung functionFood and drug administrationPharmacotherapyDrugInternal medicineLungBronchodilatorPharmacologyAsthmaBiochemistryChemistryEnzymeRespiratory and Cough-Related ResearchChronic Obstructive Pulmonary Disease (COPD) ResearchAsthma and respiratory diseases